Myriad Genetics, Inc. (MYGN) Tops Q2 EPS by 2c, Raises FY12 Outlook
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q2 EPS of $0.33, $0.02 better than the analyst estimate of $0.31. Revenue for the quarter came in at $122.8 million versus the consensus estimate of $115.28 million.
Myriad Genetics, Inc. sees FY2012 EPS of $1.24-$1.28, versus prior guidance of $1.20-$1.25 and the consensus of $1.24. Myriad Genetics, Inc. sees FY2012 revenue of $465-$475 million, versus prior guidance of $445-$465 million and the consensus of $461.45 million.
For earnings history and earnings-related data on Myriad Genetics, Inc. (MYGN) click here.
Myriad Genetics, Inc. sees FY2012 EPS of $1.24-$1.28, versus prior guidance of $1.20-$1.25 and the consensus of $1.24. Myriad Genetics, Inc. sees FY2012 revenue of $465-$475 million, versus prior guidance of $445-$465 million and the consensus of $461.45 million.
For earnings history and earnings-related data on Myriad Genetics, Inc. (MYGN) click here.